What matters first
“Peptide” is a chemical category, not a verdict on benefit, safety or legality.1 The exact molecule, formulation, route, indication, product status and human evidence must stay connected.1
Choose your next question
Connected reader paths
Peptide safety
The questions a label or marketing claim cannot answer by itself.1
Read the guide
FDA status map
Approved, compounded, investigational and research-market categories.12
Read the guide
Peptides for women over 40
A goal-by-goal evidence map without a treatment menu.1
Read the guide
Read a peptide trial
Population, comparator, outcome, route and reporting questions.
Read the guide
BPC-157
Human evidence gaps, safety and regulatory reality.12
Read the guide
MOTS-c
Preclinical interest and the limits of human evidence.1Preclinical only; human benefit and safety are not established.
Read the guide
GHK-Cu
Topical cosmetic context kept separate from injection claims.
Read the guide
CJC-1295 + ipamorelin
Combination marketing versus product-specific human data.
Read the guide
TB-500
Human data, safety and marketing-claim boundaries.
Read the guide
Gray-market literacy
COAs, sterility, research-use labels and transparency.1
Read the guide
A clearer way through the topic
Define the decision
Separate the symptom, goal, product or measurement from the promise around it.1
Match the evidence
Check population, route, outcome, study design and how directly the evidence applies.1
Keep limits visible
Look for alternatives, contraindications, uncertainty, and the point where professional care matters.
How to use this hub
Begin with status and route, then ask whether relevant human evidence exists.1 These pages do not provide injection instructions, cycles, doses, sellers or purchase paths for unapproved investigational products.12
Use the linked pages to prepare better questions. Educational material cannot diagnose, prescribe, or replace care from a qualified professional who knows your history.1
Evidence boundaries
- Human outcomes are kept separate from mechanisms and animal research.
- Women- and life-stage-specific evidence is identified when available.1
- Products, ingredients, routes and regulatory categories are not treated as interchangeable.
Authoritative starting points
Claim-level source ledger
Evidence used on this page
- Drugs@FDA: FDA-Approved Drugs. Checked 2026-08-25.
- Internal Error (). Checked 2026-08-25.
Interpretation boundary: each source is listed for the statement it supports; population and design limits remain visible.